Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Boost Pharma Aps currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to a distinct examiner and is located within a distinct art unit. This indicates a very specific focus for the company's current patent activities. The busiest examiner for the portfolio is WESTON, ALYSSA G, who is responsible for 1 busiest examiner pending action.
Because there is only 1 pending office action, the distinct examiner is the sole official currently reviewing the company's biotechnology applications. The presence of the distinct art unit further suggests that the technology is concentrated in a single specialized area of the Biotechnology & Pharmaceuticals sector. This streamlined prosecution environment means that the company's immediate goals are dependent on the feedback from WESTON, ALYSSA G, allowing for a targeted and singular legal strategy within that specific art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTON, ALYSSA G | 1 | 59.5% | +49.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577414 | Fetal Mesenchymal Stem Cells | WESTON, ALYSSA G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577414 | Fetal Mesenchymal Stem Cells | WESTON, ALYSSA G | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18577414 | Fetal Mesenchymal Stem Cells | WESTON, ALYSSA G | 1633 | §101§102§103 | Final Rejection | — | Pending | Jan 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBoost Pharma Aps has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alyssa G Weston has the most, with 1 of Boost Pharma Aps's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
